Impact of nCPAP Treatment on Liver Function in Patients With Sleep Apnea Syndrome and Nonalcoholic Steatohepatitis

University Hospital, Angers40 enrolled

Overview

This study aims to evaluate the impact of nasal continuous positive airway pressure (nCPAP) treatment on liver enzymes in patients with sleep apnea syndrome and nonalcoholic steatohepatitis. Using a cross over design, the evolution of liver enzymes will be evaluated in 40 patients during a consecutive period of 6 weeks, with and without nCPAP treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Sleep Apnea Syndrome Nonalcoholic Steatohepatitis

Interventions

nCPAPDEVICE

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 to 70 years old * Nonalcoholic steatohepatitis proven by liver biopsy * Sleep apnea syndrome proven by polysomnography with an apnea-hypopnea index \> 10 events/hour * Informed consent Exclusion Criteria: * Psychiatric disorder * Other cause of liver disease * Professional driver

Locations (1)

University Hospital Angers

Angers, France

RECRUITING

Central Contacts

Frédéric Gagnadoux, MD

CONTACT

33(0)241353695 frgagnadoux@chu-angers.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.